Preserves the ability of licensed optometrists to use hydrocodone products to treat pain, regardless of potential action by agencies of the federal government to reclassify these products as schedule II narcotics.

Authorizes the board of optometry to include schedule II hydrocodone combination products in its list of approved oral drugs.